Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
Combination shows consistent benefit across prespecified post-progression outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Both organisations enter into a long- term collaboration to expand patient access in India
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The drug will target specific genetic mutations prevalent in certain types of cancers
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Subscribe To Our Newsletter & Stay Updated
